-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-507132-21-00
10
2021-05-11
Early Parkinson's disease
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-507970-42-00
5
2021-03-31
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-507816-11-00
5
2020-08-17
Macular edema due to central retinal vein occlusion
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2024-511832-29-00
4
2020-08-05
High risk adenocarcinoma of the prostate after radical prostatectomy
(
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2023-510455-28-00
5
2020-06-10
Hypereosinophilic Syndrome (HES)
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-511940-20-00
5
2020-02-05
Parkinson's disease
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)